Our research activities, company operations, and business model focus on conducting genetic research in-house under the direction of our Chief Scientific Officer, Dr. Mark Brennan. We also work closely with Dr. Herbert Meltzer, a prominent neuroscientist, clinician, and patient advocate, to incorporate his world-renowned insight into SureGene’s model of genetic interactions that impact antipsychotic drug response and the clinical presentation of psychosis.
SureGene focuses on quantitative traits
A common genetic variation that impacts various aspects of psychopathology (endophenotypes) can identify high-impact targets for:
- Pharmacogenetics
- Differential diagnosis
Endophenotypes include cognition, obsessiveness, bizarre mentation, bizarre sensory perception, mania, depression, paranoia, and others
At SureGene, we are redefining mental illness by focusing on endophenotypes.
SureGene’s proprietary biomarker discovery process
Target identification
- Proprietary bioinformatics identifies genes in the same pathway influencing the same phenotype
Biomarker confirmation
- Confirm role in disease with the use of consented genetic samples
Product development
- Biomarker validation
- Prototype development
- Identify select partners for commercialization